OncoMatch/Clinical Trials/NCT06988059
A Study of CT0596 in Plasma Cell Leukemia
Is NCT06988059 recruiting? Yes, currently enrolling (May 2026). This Early Phase 1 trial studies CAR-T cells Infusion chimeric antigen receptor T cells for plasma cell leukemia.
Treatment: CAR-T cells Infusion chimeric antigen receptor T cells — This study is a single-arm, open-label, exploratory dose-escalation and dosefinding clinical trial to evaluate the safety, efficacy, cellular pharmacokinetics and pharmacodynamics of CT0596 cells in patients with PCL.
Check if I qualifyExtracted eligibility criteria
Cancer type
Acute Myeloid Leukemia
Acute Lymphoblastic Leukemia
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: allogeneic stem cell transplant
Previous allogeneic stem cell transplantation
Cannot have received: autologous stem cell transplant
Exception: within 12 weeks prior to signing informed consent
autologous stem cell transplantation within 12 weeks prior to signing informed consent
Cannot have received: cell therapy
Exception: within 28 days before informed consent
Have received cell therapy within 28 days before informed consent
Cannot have received: systemic therapy for disease
Exception: within 14 days or five half-lives before preconditioning
Have received treatment for the disease within 14 days or five half-lives before preconditioning
Lab requirements
Blood counts
good organ function
Kidney function
good organ function
Liver function
good organ function
Patients should have good organ function
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify